| Literature DB >> 23491820 |
Eline Suzanne Smit1, Silvia M A A Evers, Hein de Vries, Ciska Hoving.
Abstract
BACKGROUND: Although effective smoking cessation interventions exist, information is limited about their cost-effectiveness and cost-utility.Entities:
Mesh:
Year: 2013 PMID: 23491820 PMCID: PMC3636293 DOI: 10.2196/jmir.2059
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Figure 1Overview of the intervention elements received by the 3 groups.
Comparability of the 3 groups, multiple tailoring and counseling (MTC), multiple tailoring (MT), and usual care (UC), regarding demographics, baseline values of outcomes, and health care–related costs over the past 3 months (N=414).
| Variable | MTC | MT | UC |
| χ2 (df) |
| |
| Age, mean (SD) | 48.1 (12.0) | 47.8 (12.5) | 48.1 (11.3) | 0.03 (2,406) |
| .97 | |
| Male, n (%) | 60 (36.8) | 41.2 (54) | 42.9 (51) |
| 1.2 (2) | .56 | |
|
|
|
|
|
| 1.9 (2) | .76 | |
|
| High | 39 (23.9) | 30 (22.9) | 24 (20.2) |
|
|
|
|
| Medium | 68 (41.7) | 63 (48.1) | 56 (47.1) |
|
|
|
|
| Low | 56 (34.4) | 38 (29.0) | 39 (32.8) |
|
|
|
|
|
|
|
|
|
|
| |
|
| Cardiovascular diseases, n (%) | 27 (16.6) | 17 (13.0) | 18 (15.1) |
| 0.7 (2) | .69 |
|
| Respiratory diseases, n (%) | 38 (23.3) | 44 (33.6) | 36 (30.3) |
| 4.0 (2) | .14 |
|
| Diabetes, n (%) | 8 (4.9) | 6 (4.6) | 7 (5.9) |
| 0.2 (2) | .89 |
|
| Cancer, n (%) | 10 (6.1) | 12 (9.2) | 8 (6.7) |
| 1.1 (2) | .59 |
| Cigarettes smoked per day, mean (SD) | 20.6 (10.3) | 23.5 (23.2) | 21.5 (15.5) | 1.14 (2,411) |
| .32 | |
| FTNDa score (range 0-10), mean (SD) | 5.3 (2.2) | 5.6 (2.0) | 5.3 (2.1) | 0.94 (2,406) |
| .39 | |
| Utility, mean (SD)b | 0.8 (0.2) | 0.8 (0.2) | 0.8 (0.2) | 0.60 (2,375) |
| .55 | |
|
| 425.9 (1506.9) | 286.9 (436.6) | 236.9 (474.0) | 1.19 (2,369) |
| .31 | |
|
| General practitioner | 53.2 (50.2) | 61.0 (73.2) | 49.7 (55.1) | 1.11 (2,380) |
| .33 |
|
| Medical specialist | 65.4 (132.1) | 78.6 (170.9) | 87.6 (202.8) | 0.57 (2,373) |
| .57 |
|
| Hospital | 206.9 (1371.3) | 50.9 (205.2) | 47.9 (230.8) | 1.47 (2,378) |
| .23 |
|
| Alternative healer | 5.1 (25.1) | 9.4 (41.6) | 4.9 (24.2) | 0.84 (2,379) |
| .44 |
|
| Mental health care | 30.3 (133.5) | 24.3 (100.8) | 38.2 (186.5) | 0.27 (2,380) |
| .76 |
|
| Prescribed and OTC medication | 26.7 (78.8) | 36.4 (95.5) | 13.6 (58.4) | 2.37 (2,381) |
| .10 |
|
| Medical aids and assistive devices | 1.7 (4.1) | 3.4 (12.6) | 1.9 (4.8) | 1.73 (2,380) |
| .18 |
|
| Other care | 26.0 (268.3) | 19.2 (166.4) | 12.5 (65.7) | 0.15 (2,379) |
| .86 |
a Fagerström Test for Nicotine Dependence (0=not addicted, 10=highly addicted)
b Based on the Dutch algorithm for the EQ-5D scores.
c Costs for prior 3 months.
Mean annual costsa per participant in the MTC, MT, and UC groups.
| Cost type | Costs per group (€) | 95% CIb | |||||||
|
| MTC | MT | UC | MTC–MT |
| UC–MT | MTC–UC | ||
|
|
|
|
|
|
|
| |||
|
| Intervention costs (n=384) | 57.70 | 7.70 | 0 |
|
|
| ||
|
|
|
|
|
|
|
| |||
|
| General practitioner (n=384) | 157 (14) | 180 (27) | 139 (17) | –86.1 to 32.3 | –105.8 to 15.5 | –25.4 to 61.4 | ||
|
| Medical specialist (n=374) | 298 (52) | 251 (62) | 224 (48) | –115.8 to 198.1 | –188.3 to 116.6 | –61.2 to 213.8 | ||
|
| Hospital (n=380) | 610 (288) | 267 (106) | 172 (84) | –139.7 to 1054.7 | –374.0 to 161.1 | –17.0 to 1133.4 | ||
|
| Alternative healer (n=382) | 17 (6) | 29 (13) | 18 (9) | –42.9 to 13.7 | –43.1 to 18.6 | –23.4 to 18.8 | ||
|
| Mental health care (n=384) | 106 (39) | 95 (34) | 131 (71) | –92.2 to 109.8 | –97.1 to 209.4 | –200.2 to 111.9 | ||
|
| Prescribed and OTC smoking cessation medication (n=384) | 148 (24) | 144 (30) | 90 (23) | –72.7 to 79.1 | –129.6 to 18.5 | –9.0 to 124.6 | ||
|
| Smoking cessation aids (n=384) | 20 (10) | 15 (10) | 19 (14) | –21.6 to 32.5 | –27.9 to 41.0 | –34.4 to 32.3 | ||
|
| Other care (n=382) | 122 (87) | 21 (12) | 41 (22) | –15.9 to 293.6 | –24.7 to 72.4 | –45.9 to 281.7 | ||
|
| Overall health care–related costs (n=370) | 1564 (338) | 1016 (158) | 761 (122) | –95.4 to 1381.4 | –642.2 to 139.1 | 194.3-1611.8 | ||
a Volumes and price details are available upon request.
b Based on 5000 bootstrap replications.
Mean annual effect on smoking abstinence, QALY, and addiction level in the MTC, MT, and UC groups.
| Effects | MTC | MT | UC |
| χ2 (df) |
|
| Prolonged abstinent (n=414), n (%) | 14 (8.6) | 20 (15.2) | 12 (10.1) |
| 3.4 (2) | .19 |
| QALY (EQ-5D)a (n=384), mean (SD) | 0.86 (0.15) | 0.83 (0.21) | 0.84 (0.21) | 0.89 (2,381) |
| .41 |
| 7 days abstinent (n=414), n (%) | 20 (12.3) | 27 (20.5) | 15 (12.6) |
| 4.6 (2) | .10 |
| FTNDb score (n=409), mean (SD) | 4.76 (2.41) | 5.21 (2.30) | 4.81 (2.46) | 1.40 (2,406) |
| .25 |
a Based on the Dutch algorithm for the EQ-5D scores.
b Fagerström Test for Nicotine Dependence (0=not addicted, 10=highly addicted); reversed range.
Incremental costs and effects per abstinent smoker and per QALY gained for the MTC, MT, and UC groups with a willingness-to-pay threshold of €18,000.
| Intervention | Incremental costs (€) | Incremental probabilitya | Incremental costsb (€) | |
|
|
|
|
| |
|
| UC |
|
|
|
|
| MT vs UC | 255 | .05 | 5100 |
|
| MTC vs UC | 806 | –.02 | Dominatedd |
|
| MTC vs MT | 551 | –.07 | Dominatede |
|
|
|
|
| |
|
| UC |
|
|
|
|
| MT vs UC | 255 | –.01 | Dominatedg |
|
| MTC vs UC | 806 | .02 | 40,300 |
|
| MTC vs MT | 551 | .03 | 18,367 |
a Probability of being abstinent/gaining 1 QALY.
b Per abstinent participant or per QALY; calculated according to the formula ICER/ICUR=(Ci–Cc)/(Ei–Ec); additional information available in Multimedia Appendix 1.
c Coded as 1=not abstinent and 2=abstinent.
d ICER=–40.300.
e ICER=–7.871.
f Based on the Dutch algorithm for the EQ-5D scores.
g ICUR=–25.500.
Results from cost-effectiveness and cost-utility analyses based on 1000 bootstrap replications.
| Type of analysis | Group, n | Probability of highest net monetary benefita, % | |||||
|
| MTC | MT | UC | MTC | MT | UC | |
|
|
|
|
|
|
|
| |
|
| Prolonged abstinencef | 145 | 121 | 104 | 0 | 78 | 21 |
|
| QALY (EQ-5D)b | 145 | 121 | 104 | 18 | 18 | 64 |
|
|
|
|
|
|
|
| |
|
| 7-day ppac,f | 145 | 121 | 104 | 1 | 88 | 11 |
|
| FTND scored | 135 | 115 | 96 | 50 | 6 | 45 |
|
|
|
|
|
|
|
| |
|
| Prolonged abstinencef | 145 | 121 | 104 | 1 | 76 | 24 |
|
| QALY (EQ-5D)b | 145 | 121 | 104 | 19 | 15 | 66 |
aWith a willingness-to-pay threshold of €18,000.
bBased on the Dutch algorithm for the EQ-5D scores.
cppa: point prevalence abstinence.
dFTND: Fagerström Test for Nicotine Dependence (0=not addicted, 10=highly addicted).
eIncrease in program costs from €57.70 to €141.89 (MTC group) and from €7.70 to €82.24 (MT group) caused by the inclusion of patient costs.
fCoded as 1=not abstinent and 2=abstinent.
Figure 2Cost-effectiveness acceptability curve for the 3 treatments studied: MTC, MT, and UC.
Figure 3Cost-utility acceptability curve for the 3 treatments studied: MTC, MT, and UC.